Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- James Malone, MD
Eli Lilly and Company
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Beijing, China
- Research Site
Guangzhou, China
- Research Site
Nanjing, China
- Research Site
Shanghai, China
- Research Site
Sichuan, China
- Research Site
Chennai, India
- Research Site
Mumbai, India
- Research Site
Pune, India
- Research Site
Seoul, South Korea
- Research Site
Sungnam City, South Korea
- Research Site
Chiayi City, Taiwan
- Research Site
Taichung, Taiwan
- Research Site
Tainan, Taiwan
- Research Site
Taipei, Taiwan
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2006
- Primary completion
- 30 Apr 2007
- Completion
- 30 Apr 2007
- Last update posted
- 23 Feb 2015
- Registered enrollment
- 466
- Registry id
- NCT00324363
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.